OpenLB
Open Library of Bioscience
Advanced Search
Antimicrobial resistance and infection control
2019;8 66.

In vitro polymyxin activity against clinical multidrug-resistant fungi.

Hanane Yousfi, Stéphane Ranque, Jean-Marc Rolain, Fadi Bittar
Author Information
  1. Hanane Yousfi: Aix Marseille Univ, IRD, APHM, MEPHI, IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France.
  2. Stéphane Ranque: Aix Marseille Univ, IRD, APHM, SSA, VITROME, IHU-Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France.
  3. Jean-Marc Rolain: Aix Marseille Univ, IRD, APHM, MEPHI, IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France.
  4. Fadi Bittar: Aix Marseille Univ, IRD, APHM, MEPHI, IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France. ORCID
PMID: 31044071 DOI: 10.1186/s13756-019-0521-7

Abstract

Background: Although antifungals are available and usually used against fungal infections, multidrug-resistant (MDR) fungal pathogens are a growing problem for public health. Moreover, fungal infections have become more prevalent nowadays due to the increasing number of people living with immunodeficiency. Thus, previously rarely-isolated and/or unidentified fungal species including MDR yeast and moulds have emerged around the world. Recent works indicate that polymyxin antibiotics (polymyxin B and colistin) have potential antifungal proprieties. Therefore, investigating the in vitro activity of these molecules against clinical multidrug-resistant yeast and moulds could be very useful.
Methods: In this study, a total of 11 MDR yeast and filamentous fungal strains commonly reported in clinical settings were tested against polymyxin antibiotics. These include strains belonging to the , and yeast genera, along with others belonging to the , , , and mould genera. The fungicidal or fungistatic action of colistin against clinical yeast strains was determined by the time-kill study. Further, a checkerboard assay for its combination with antifungal agents, usually used in clinical practices (amphotericin B, itraconazole, voriconazole), was carried out against multi-drug resistant fungal strains.
Results: Polymyxin B and colistin exhibited an antifungal activity against all MDR fungal strains tested with MICs ranging from 16 to 128 μg/ml, except for the species. In addition, colistin has a fungicidal action against yeast species, with minimum fungicidal concentrations ranging from 2 to 4 times MICs. It induces damage to the MDR membrane. A synergistic activity of colistin-amphotericin B and colistin-itraconazole associations against and strains, respectively, and colistin-fluconazole association against was demonstrated using a checkerboard microdilution assay.
Conclusion: colistin could be proposed, in clinical practice, in association with other antifungals, to treat life-threatening fungal infections caused by MDR yeasts or moulds.

Keywords

Candida albicans MDR-fungi Molds Polymyxin antibiotics Repurposing-drug

References

  1. Mycoses. 2016 Nov;59(11):678-690 [PMID: 27061755]
  2. J Med Microbiol. 1970 Aug;3(3):529-38 [PMID: 4319621]
  3. Int J Antimicrob Agents. 2017 Jun;49(6):740-748 [PMID: 28433743]
  4. Clin Microbiol Rev. 2008 Jul;21(3):449-65 [PMID: 18625681]
  5. Indian J Ophthalmol. 2016 May;64(5):346-57 [PMID: 27380973]
  6. J Antimicrob Chemother. 2010 May;65(5):931-8 [PMID: 20167587]
  7. J Cyst Fibros. 2009 May;8(3):211-7 [PMID: 19372063]
  8. Antimicrob Agents Chemother. 2014 Oct;58(10):5795-800 [PMID: 25049251]
  9. Int J Antimicrob Agents. 2018 Jan;51(1):10-15 [PMID: 28669833]
  10. Antimicrob Agents Chemother. 1998 Jul;42(7):1587-91 [PMID: 9660988]
  11. Int J Antimicrob Agents. 2018 Jul;52(1):11-13 [PMID: 29580929]
  12. Antimicrob Agents Chemother. 2016 Oct 21;60(11):6998-6999 [PMID: 27620480]
  13. Afr J Infect Dis. 2010;4(1):1-6 [PMID: 23878695]
  14. Antimicrob Agents Chemother. 2010 Jan;54(1):484-90 [PMID: 19858263]
  15. Transplant Proc. 2019 Jan - Feb;51(1):202-205 [PMID: 30661895]
  16. Antimicrob Agents Chemother. 2016 Dec 27;61(1): [PMID: 27821445]
  17. J Antimicrob Chemother. 2013 Jun;68(6):1285-96 [PMID: 23378416]
  18. Intern Med J. 2007 Jul;37(7):495-8 [PMID: 17547727]
  19. Mycoses. 2013 May;56(3):297-303 [PMID: 23170818]
  20. Ann N Y Acad Sci. 2019 Jan;1435(1):57-78 [PMID: 29762860]
  21. Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2234-9 [PMID: 22308411]
  22. Microb Drug Resist. 2019 Jan/Feb;25(1):63-71 [PMID: 30129868]
  23. Lancet Infect Dis. 2016 Feb;16(2):147 [PMID: 26711360]
  24. BMJ Case Rep. 2016 Aug 03;2016: [PMID: 27489066]
  25. Br J Haematol. 2014 Aug;166(4):471-84 [PMID: 24749533]
  26. Int J Antimicrob Agents. 2017 Nov;50(5):599-606 [PMID: 28669835]
  27. Clin Infect Dis. 2008 Jan 1;46(1):120-8 [PMID: 18171227]
  28. Cold Spring Harb Perspect Med. 2016 Oct 3;6(10): [PMID: 27503996]
  29. J Fungi (Basel). 2017 Aug 26;3(3): [PMID: 29371563]
  30. Eukaryot Cell. 2007 Nov;6(11):1933-42 [PMID: 17873085]
  31. FEMS Yeast Res. 2014 Nov;14(7):1068-79 [PMID: 25154541]
  32. Front Microbiol. 2014 Nov 26;5:643 [PMID: 25505462]
  33. Pharmacol Res Perspect. 2015 Jun;3(3):e00149 [PMID: 26171228]
  34. Int J Antimicrob Agents. 2017 Nov;50(5):617-621 [PMID: 28802855]
  35. Clin Infect Dis. 2005 Sep 1;41(5):634-53 [PMID: 16080086]
  36. J Clin Microbiol. 2007 Jun;45(6):1811-20 [PMID: 17428932]
  37. Br J Ophthalmol. 2004 Jan;88(1):25-8 [PMID: 14693766]
  38. Clin Infect Dis. 2001 Aug 15;33(4):550-5 [PMID: 11462194]
  39. Am J Med. 2012 Jan;125(1 Suppl):S3-13 [PMID: 22196207]
  40. Ann Intensive Care. 2016 Dec;6(1):26 [PMID: 27033711]

MeSH Term

Antifungal Agents
Colistin
Drug Repositioning
Drug Resistance, Multiple, Fungal
Fungi
Humans
Microbial Sensitivity Tests
Polymyxin B
Polymyxins

Chemicals

Antifungal Agents
Polymyxins
Polymyxin B
Colistin
Journal Article Research Support, Non-U.S. Gov't
Article has an altmetric score of 15

Word Cloud

Created with Highcharts 10.0.0fungalMDRyeastclinicalstrainscolistinpolymyxinBactivityinfectionsmultidrug-resistantspeciesmouldsantibioticsantifungalfungicidalantifungalsusuallyusedvitrostudytestedbelonginggeneraactioncheckerboardassayPolymyxinMICsrangingassociationBackground:AlthoughavailablepathogensgrowingproblempublichealthMoreoverbecomeprevalentnowadaysdueincreasingnumberpeoplelivingimmunodeficiencyThuspreviouslyrarely-isolatedand/orunidentifiedincludingemergedaroundworldRecentworksindicatepotentialproprietiesThereforeinvestigatingmoleculesusefulMethods:total11filamentouscommonlyreportedsettingsincludealongothersmouldfungistaticdeterminedtime-killcombinationagentspracticesamphotericinitraconazolevoriconazolecarriedmulti-drugresistantResults:exhibited16128 μg/mlexceptadditionminimumconcentrations24timesinducesdamagemembranesynergisticcolistin-amphotericincolistin-itraconazoleassociationsrespectivelycolistin-fluconazoledemonstratedusingmicrodilutionConclusion:proposedpracticetreatlife-threateningcausedyeastsfungiCandidaalbicansMDR-fungiMoldsRepurposing-drug

Similar Articles

Cited By